<DOC>
	<DOCNO>NCT01991457</DOCNO>
	<brief_summary>The goal research test conditioning regimen , fludarabine total body irradiation ( FluTBI ) , lead safer effective stem cell transplant treatment regimen ALL patient older 40 year age and/or young patient high risk medical condition . The primary objective establish efficacy allo HCT old ALL patient use myeloablative FluTBI condition regimen . The investigator also assess safety toxicity allo HCT old ALL patient use myeloablative FluTBI condition regimen .</brief_summary>
	<brief_title>Fludarabine / Total Body Irradiation Regimen ALLO HCT Acute Lymphoblastic Leukemia</brief_title>
	<detailed_description />
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<mesh_term>Fludarabine phosphate</mesh_term>
	<mesh_term>Vidarabine</mesh_term>
	<criteria>Disease Criteria : ALL complete remission ( CR ) time transplant . Remission define `` less 5.0 % bone marrow lymphoblasts morphology , '' determine bone marrow aspirate obtain within 2 week study registration . Philadelphia chromosome positive ALL allow . Lymphoid blastic crisis CML include ( provide patient achieve CR ) . Age Criteria : Equal age 40 65 year . If young 40 , must comorbidities preclude patient undergo CyTBI condition regimen . Organ Function Criteria : All organ function test do within 28 day study registration . Cardiac : Left ventricular ejection fraction ( LVEF ) ≥ 50 % MUGA ( Multi Gated Acquisition ) scan echocardiogram . Pulmonary : FEV1 ( Forced expiratory volume 1 second ) FVC ( Forced vital capacity ) ≥ 50 % predict , DLCO ( alveolar diffusion capacity carbon monoxide ) ( correct hemoglobin ) ≥ 50 % predict . Renal : The estimated creatinine clearance ( CrCl ) must equal great 60 mL/min/1.73 m2 calculate CockcroftGault Formula : CrCl = ( 140age ) x weight ( kg ) x 0.85 ( female ) /72 x serum creatinine ( mg/dL ) . Hepatic : Serum bilirubin 2.0 g/dL Aspartate transaminase ( AST ) /alanine transaminase ( ALT ) 2.5 ULN Alkaline phosphatase 2.5 ULN Performance status : Karnofsky ≥ 70 % Consent : Patient must inform investigational nature study accordance institutional federal guideline ability provide write informed consent prior initiation studyrelated procedure , ability , opinion principal investigator , comply requirement study . Presence willing adult HLAmatched sibling ( exclude identical twin ) HLAmatched unrelated donor meeting criterion routine allo HSCT . All donor evaluate eligibility suitability per standard care accord FACT NMDP guideline . Noncompliant medication . No appropriate caregiver identify . HIV1 ( Human Immunodeficiency Virus1 ) HIV2 positive Active lifethreatening cancer require treatment ALL Uncontrolled medical psychiatric disorder . Uncontrolled infection , define positive blood culture within 72 hour study entry , evidence progressive infection image study chest CT scan within 14 day registration . Active central nervous system ( CNS ) leukemia Preceding allogeneic HSCT Receiving intensive chemotherapy within 21 day registration . Maintenance type chemotherapy allow .</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>ALL</keyword>
</DOC>